Overview
The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.
Description
Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10.
Treatment plan will be initiated to all patients according to the burn ICU protocol.
According to the lab results, interleukin 6 and procalcitonin will guide the investigators to take decisions regarding clinical improvement and ICU stay.
Eligibility
Inclusion Criteria:
- Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.
- patients with burn percentage of 25% to 50% of total body surface area
- patients with second to third degree burns
- ASA 1 and ASA 2 patients
Exclusion Criteria:
- Burn percentage more than 50% or less than 25% of total body surface area
- Having autoimmune diseases
- Cancer patients
- ASA 3 and ASA 4 patients